Gentris Corporation, a global leader in applied clinical pharmacogenomics, announced today that they have appointed Karen Weck, MD, as a consulting medical director. Dr Weck replaces the previous medical director to continue Gentris’ CLIA program and help expand opportunities to develop new biomarkers.
“Gentris is very fortunate to have Dr. Weck join us as a consulting medical director,” said Dawn Bordeaux, chief operating officer of Gentris. “She will be an invaluable asset to our quality program as we continue to transition into a CLIA regulatory environment.”
Dr Weck brings over 20 years of experience to Gentris, including certified expertise in both clinical and molecular genetic pathology, which helps the company to continue, and expand upon, its notable successes. Dr Weck’s distinguished professional history includes numerous research grants, a variety of honors and awards, multiple inventions, dozens of publications, and membership in several national organizations including the American Society of Human Genetics, the Association for Molecular Pathology, and the Academy of Clinical Laboratory Physicians and Scientists.
Currently, Dr Weck is affiliated with the University of North Carolina, serving as the director for molecular genetics, associate director of molecular pathology for the School of Medicine, and associate director of the UNC Institute of Pharmacogenomics and Individualized Therapy. She also holds positions as associate professor of both genetics and pathology and laboratory medicine.
Dr Karen Weck received both her bachelor of science degree and medical degree from Duke University, and completed her residency at Washington University School of Medicine. Dr Weck has also received board certification in molecular genetic pathology and clinical pathology from the American Board of Pathology.